IMR Press / CEOG / Volume 43 / Issue 5 / DOI: 10.12891/ceog3004.2016

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
The protective effect of the proteasome inhibitor bortezomib on the uterus of ovariectomized rats
Show Less
1 Kafkas University, Medical Faculty, Department of Histology and Embryology, Kars
2 Gaziantep University, Medical Faculty, Department of Histology and Embryology, Gaziantep
3 Kafkas University, Medical Faculty, Department of Physiology, Kars
4 Sakarya University, Medical Faculty, Department of Obstetrics and Gynecology, Sakarya (Turkey)
Clin. Exp. Obstet. Gynecol. 2016, 43(5), 737–741;
Published: 10 October 2016

Bortezomib (BORT) is an anti-tumour agent that inhibits proteasome, which is responsible for the degradation of many intracellular proteins. Although some side-effects and chemotherapeutic effects of BORT are known, there has not been enough research regarding its effects on different tissues of proteasome inhibition in the senile period (post-menopausal). The aim of this study was to investigate the safety of using BORT during the post-menopausal period. The post-menopausal effects of BORT were investigated on ovariectomized (OVX) Spraque-Dawley rats. The female rats were separated into three groups: control, ovariectomized (OVX), and OVX + BORT. OVX and OVX + BORT groups consisted of six rats in each. BORT was administered intraperitoneally in a dosage of 0.2 mg/kg two days a week for four weeks after OVX. The uteri of the rats were investigated using morphometrical, histopathological, and immunohistopathological methods. A striking atrophy in the endometrium and myometrium was observed due to an estrogen deficiency in the OVX group. The partial protective effect of BORT administration was observed morphometrically and histopathologically. In immunohistochemical research, cytoplasmic NF-κB activity was observed in the presence of proteasome inhibition in the endometrium. In light of these findings, the limited protective effects of post-menopausal BORT administration are worth mentioning.
Protective effects
Back to top